Frankfurt In the past two years, the corona pandemic has given the pharmaceutical industry the strongest sales boost in decades. But the boom is abating and the industry will have to prepare for a dip in growth in 2023.
The differences in performance will again be large, albeit with the opposite sign. Those companies that have recently benefited from demand for Covid vaccines and drugs are heading for the sharpest losses in 2023.
Overall, the British data analysis company Evaluate Pharma is still expecting slight growth of around one percent for the year. In the following years, the growth rate should normalize to six to eight percent.
New drugs for diabetes, cancer, obesity, autoimmune diseases and possibly also for Alzheimer’s promise additional business for a number of players in the new year. In addition, several new gene and cell therapies are expected to deliver their first significant sales in 2023.
Top jobs of the day
Find the best jobs now and
be notified by email.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue